Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

NYSE Amex grants Interleukin Genetics extension for regaining compliance

Interleukin Genetics, Inc. announced today that the Corporate Compliance Staff of the NYSE Amex LLC has granted the Company an extension to meet the Exchange's continued listing standards and become compliant. The Company will remain listed up to June 23, 2010, subject to periodic review by the Exchange staff during the extension period of progress towards the Company's plan to regain compliance.

22 Mar 2010

Caltech-led trial demonstrates feasibility of nanoparticles and RNAi-based therapeutics for treating cancer

A California Institute of Technology -led team of researchers and clinicians has published the first proof that a targeted nanoparticle-used as an experimental therapeutic and injected directly into a patient's bloodstream-can traffic into tumors, deliver double-stranded small interfering RNAs (siRNAs), and turn off an important cancer gene using a mechanism known as RNA interference (RNAi).

22 Mar 2010

Pressure BioSciences announces presentations on advantages of PCT

Pressure BioSciences, Inc. today announced that five presentations on the advantages of pressure cycling technology (PCT) in the preparation, processing, identification, and quantification of proteins were made at last week's annual meeting of US HUPO (Human Proteomics Organization) in Denver, Colorado.

From Thermo Fisher Scientific Inc. 19 Mar 2010

EDP Biotech briefs Tennessee state legislators on ColoMarker colon cancer test

EDP Biotech, a Knoxville-based company today briefed Tennessee state legislators on its revolutionary ColoMarker™ colon cancer test which potentially could save 50,000 lives and more than $12 billion in healthcare costs annually in the U.S. Legislators were also provided the opportunity to personally experience the ColoMarker™ test by enrolling in the control study group for EDP’s latest research.

18 Mar 2010

Virtuoso Digital Pathology Software: BioImagene adds Companion Algorithms for colon cancer

BioImagene, Inc., the leading provider of end-to-end digital pathology solutions, today announced the availability of Companion Algorithms™ for colon cancer in their Virtuoso™ Digital Pathology Software. BioImagene’s Companion Algorithms are unique in the digital pathology industry as they are specific to a biomarker and a tissue type. Therefore, pathologists are not faced with the challenges of customizing generic algorithms in order to make them work.

18 Mar 2010

Agendia to participate in groundbreaking clinical trial for breast cancer

Agendia, a world leader in molecular cancer diagnostics, announced today it will participate in the highly anticipated I-SPY 2 TRIAL for breast cancer, set to launch at the first of nearly twenty research sites.

18 Mar 2010

HDC, SPM enter into development and licensing agreements with Quest Diagnostics

Health Discovery Corporation and Smart Personalized Medicine, LLC announced today that they have entered into development and related licensing agreements with Quest Diagnostics Incorporated, the world’s leading provider of diagnostic testing, information and services.

From Quest Diagnostics 17 Mar 2010

Clarient's Ovotax test may help improve patients’ response to taxane therapy

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that data from a new study shows that Clarient's Ovotax™ assay may effectively predict which ovarian cancer patients will respond favorably to taxane therapy and could, therefore, be spared the potential side effects of this rigorous and sometimes toxic chemotherapy agent.

17 Mar 2010

Compugen announces validation of IDD discovery platform for identification of cell penetrating peptides

Compugen Ltd. announced today the development and validation of its Intracellular Drug Delivery (IDD) discovery platform for identification of cell penetrating peptides. Compugen also announced that as part of the validation process for the new platform, more than twenty novel peptides, predicted and selected in silico, demonstrated the predicted cell penetrating properties in initial experimental validation studies.

17 Mar 2010

Discovery of MiR-451 molecule may serve as a biomarker for brain tumor

Cancer cells in rapidly growing brain tumors must adjust to periods of low energy or die. When energy levels are high, tumor cells grow and proliferate. When levels are low, the cells grow less and migrate more.

15 Mar 2010

VisEn Medical introduces VivoTag 680 XL fluorescent dye for labeling biomolecules

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new VivoTag® 680 XL fluorescent dye for labeling biomolecules in a broad range of in vitro and in vivo imaging applications.

12 Mar 2010

PSA test is still the best option for diagnosing prostate cancer

When it comes to the documented 40 percent effectiveness of PSA testing in preventing death from prostate cancer, neither the American Cancer Society nor the discoverer of the PSA protein, Richard Ablin, are telling the public the complete story.

12 Mar 2010

Molecular master switch plays a key role in maturation process of brain cells

About four out of every 10 cells in the brain are so-called oligodendrocytes. These cells produce the all-important myelin that coats nerve tracts, ensuring fast, energy-efficient transmission of nerve impulses.

11 Mar 2010

PBI and TDI announce strategic licensing and collaborative research and development agreement

Pressure BioSciences, Inc. and Target Discovery, Inc.,, today announced a strategic product licensing, manufacturing, co-marketing, and collaborative research and development agreement. Under the terms of the Agreement, PBI has been licensed by TDI to manufacture and sell a highly innovative line of chemicals used in the preparation of tissues for scientific analysis.

11 Mar 2010

BIOCRATES Life Sciences, CHENOMX announce co-marketing agreement

Austrian biomarker developer BIOCRATES Life Sciences AG announced today that it entered a co-marketing agreement with Canadian-based CHENOMX Inc. Both enterprises focus on a new and highly promising technology aimed at generating a metabolic profile of the human organism that can be used to monitor the effects of disease, nutrition, toxins, environment, or drugs on an organism.

10 Mar 2010

Ischemix commences CMX-2043 Phase 2a trial for prevention of peri-operative ischemia-reperfusion injury

Ischemix today announced the initiation of patient accrual in a multi-center Phase 2a clinical trial of CMX-2043 for the prevention of peri-operative ischemia-reperfusion injury in patients undergoing elective percutaneous coronary intervention (PCI) procedures. CMX-2043 is a cardio-protective drug that combines Akt pathway-mediated cell survival effects and anti-oxidant activity in a single small molecule.

9 Mar 2010

Atherotech to exhibit VAP Cholesterol Test at ACC 2010

Atherotech Inc. today announced it will be presenting research in two poster sessions and exhibiting its VAP® Cholesterol Test in booth #1311 at the American College of Cardiology (ACC) 59th Annual Scientific Session Exposition. The annual meeting takes place March 14-16, 2010, at the Georgia World Congress Center in Atlanta.

9 Mar 2010

BG Medicine enters into development and commercialization agreement with Abbott Laboratories

BG Medicine, Inc. today announced that it has entered into an agreement with Abbott Laboratories to extend its current development and commercialization collaboration to include the development of a galectin-3 test for Abbott Point of Care’s i-STAT® System.

9 Mar 2010

Positive Phase 2 data from Nektar Therapeutics' NKTR-102 study in women with platinum-resistant ovarian cancer

Nektar Therapeutics today announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients were enrolled with platinum-resistant disease and were evaluable for the secondary endpoint of progression-free survival (PFS).

8 Mar 2010

Ricerca Biosciences to acquire Discovery and Preclinical business of MDS Pharma Services

Ricerca Biosciences, LLC, announced today the finalization of the acquisition of the Discovery and Preclinical business of MDS Pharma Services with facilities and almost 600 associates in Bothell, Washington; Lyon, France; and Taipei, Taiwan.

8 Mar 2010

Biomarker News and Research

Further Reading

NYSE Amex grants Interleukin Genetics extension for regaining compliance

Caltech-led trial demonstrates feasibility of nanoparticles and RNAi-based therapeutics for treating cancer

Pressure BioSciences announces presentations on advantages of PCT

EDP Biotech briefs Tennessee state legislators on ColoMarker colon cancer test

Virtuoso Digital Pathology Software: BioImagene adds Companion Algorithms for colon cancer

Agendia to participate in groundbreaking clinical trial for breast cancer

HDC, SPM enter into development and licensing agreements with Quest Diagnostics

Clarient's Ovotax test may help improve patients’ response to taxane therapy

Compugen announces validation of IDD discovery platform for identification of cell penetrating peptides

Discovery of MiR-451 molecule may serve as a biomarker for brain tumor

VisEn Medical introduces VivoTag 680 XL fluorescent dye for labeling biomolecules

PSA test is still the best option for diagnosing prostate cancer

Molecular master switch plays a key role in maturation process of brain cells

PBI and TDI announce strategic licensing and collaborative research and development agreement

BIOCRATES Life Sciences, CHENOMX announce co-marketing agreement

Ischemix commences CMX-2043 Phase 2a trial for prevention of peri-operative ischemia-reperfusion injury

Atherotech to exhibit VAP Cholesterol Test at ACC 2010

BG Medicine enters into development and commercialization agreement with Abbott Laboratories

Positive Phase 2 data from Nektar Therapeutics' NKTR-102 study in women with platinum-resistant ovarian cancer

Ricerca Biosciences to acquire Discovery and Preclinical business of MDS Pharma Services

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News